Back

Lowering the neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone: potential implications for cardiovascular events in high risk patients

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 2 - Coronary artery disease: from bench to bedside Inflammation and microcirculation ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Jan Johansson

Resverlogix Inc., San Francisco (United States of America)

71 More presentations in this session

Presentation thumbnail
Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
Doctor G. Chi (Boston, US)
Abstract Slides
Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation
Professor P. Pignatelli Spinazzola (Rome, IT)
Abstract Slides
Presentation thumbnail
Factor V Leiden related risk of thromboembolic and bleeding complications in patients with established coronary heart disease.
Doctor B. Mahmoodi (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Factor V Leiden and prothrombin G20210A mutations in patients with premature myocardial infarction.
Professor L. Rallidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Angiographic and hemodynamic modifications of Myocardial Bridge during supine bicycle exercise
Doctor J. Adjedj (Saint Laurent du Var, FR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Coronary artery disease: from bench to bedside

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources